Soliton Receives Additional Patent for Breakthrough Acoustic Shockwave Technology
February 26 2019 - 7:30AM
Rapid Acoustic Pulse device granted
patent in China; bringing a total of 38 issued or
pending patents
Soliton, Inc., (Nasdaq: SOLY), (“Soliton” or the “Company”), a
medical technology company that has developed a new acoustic
shockwave device, today announced that the National Intellectual
Property Administration (Chinese Patent Office) has issued a notice
of grant for Chinese Patent Application No. 201280041817.2, based
on International Application No.PCT/IS2012/046674; Entitled
“Apparatus for Generating Therapeutic Shockwaves And Applications
of Same,” by Christopher C. Capelli.
------------------------Join our more than 208K fans here to
follow the Company:
https://www.soly-investors.com------------------------
Dr. Chris Capelli, CEO of Soliton, said, “The granting of
this patent is an important milestone for Soliton. With the
issuance of this patent in the People’s Republic of China (“PRC”)
for our leading-edge Rapid Acoustic Pulse (“RAP”) technology and
with our pending United States patents, we are well positioned to
develop two of the major consumer markets in the world. We have a
strong portfolio that now numbers 38 issued and pending patents
that we believe provides Soliton a meaningful competitive advantage
in removing unwanted tattoos in about one-third of the time of
traditional procedures, with less pain and discomfort, and at a
lower overall cost.”
Soliton has discovered other capabilities of the RAP technology
during preclinical testing, including the potential to assist
existing fat reduction technology in the reduction of fat as well
as potentially reducing the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth. Importantly, this potential indication could
position Soliton RAP as a stand-alone device, without the need for
lasers or other procedures.
Dr. Capelli concluded, “If our ongoing clinical trials prove to
be effective in cellulite and fat removal, we will dramatically
expand our addressable markets. We are excited with the
opportunities ahead in the coming years.”
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company’s first planned commercial product will use rapid pulses of
designed acoustic shockwaves to dramatically accelerate the removal
of unwanted tattoos. The Company is based in Houston, Texas, and is
actively engaged in bringing this device to the market. The Company
expects to file for premarket clearance with the U.S. Food and Drug
Administration ("FDA") for its’ first device in the first quarter
of 2019 and expects to receive clearance to market the device in
mid 2019. This initial filing is limited to the Company’s device
used in conjunction with the 1064 nm Q-switched laser to enable
effective multiple pass laser treatments in a single office session
to accelerate removal of black tattoos on the arms, legs and torso
in Fitzpatrick Skin Type I-III individuals. While the Company
believes its’ technology has many potential applications, the
Company has initially focused on the removal of tattoos, where both
animal and human studies have shown promising results. The current
standard of care for tattoo removal is to use a Q-switched (pulsed)
laser to ablate the tattoo ink particles into pieces small enough
for the body’s natural processes to remove them. Unfortunately,
this current method is highly inefficient, requiring up to 10 or
more office visits to achieve acceptable results. A clinical trial
has demonstrated that using the Company’s RAP device, in
conjunction with a Q-switched laser, has the potential to produce
similar results in just 2 to 3 office visits versus the industry
average of 10 or more with a stand-alone laser. The Company
believes this “Soliton” method can not only dramatically accelerate
tattoo removal, but also has the potential to lower removal cost
for patients, while increasing profitability to practitioners, and
to reduce the potential for unwanted side effects from current
laser removal methods.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton RAP to
accelerate tattoo fading or fat removal and/or to reduce cellulite,
and whether future clinical trials related to the
acceleration of existing fat removal technologies and cellulite are
successful. These statements relate to future events, future
expectations, plans and prospects. Although Soliton believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Risk Factors" in the Form 1-A we filed
with the SEC on February 13, 2019. Any forward-looking
statements contained in this release speak only as of its date.
Soliton undertakes no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:Joe Dorame, Joe Diaz & Robert
BlumLytham Partners,
LLC602-889-9700soly@lythampartners.com
Soliton (NASDAQ:SOLY)
Historical Stock Chart
From May 2024 to Jun 2024
Soliton (NASDAQ:SOLY)
Historical Stock Chart
From Jun 2023 to Jun 2024